ConductScience.org, home

Comparison · NCT05736861-sae

Arm A - Ivermectin 400 vs Arm A - Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm A - Ivermectin 400 vs Arm A - Placebo: serious adverse events. Trial comparisons, record NCT05736861-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05736861-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01590.009320.027wilson
Risk in group 20.0220.01380.0349wilson
Risk difference, group 1 minus group 2-0.00605-0.02060.00777newcombe hybrid score
Risk ratio, group 1 over group 20.7240.3541.48log
Odds ratio, group 1 over group 20.720.3471.49log
Number needed to treat, for one fewer participant with a serious adverse event on Arm A - Ivermectin 400 than on Arm A - Placebo165from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm A - Ivermectin 400
Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg.~Ivermectin: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
13817EG000
Group 2Arm A - Placebo
Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing.~Placebo: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
17774EG001

Harm

What it counts
Total, serious adverse events
Time frame
Up to 90 days

Source ClinicalTrials.gov

Trial

Title
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
NCT number
NCT05736861
Phases
PHASE3
Conditions
Covid19
Interventions
Ivermectin, Placebo
Lead sponsor
Susanna Naggie, MD
Results first posted
2023-04-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05736861-sae